A sign displays the types of COVID-19 vaccination doses available at a Walgreens mobile bus clinic on June 25, 2021 in Los Angeles, California.
Mario Tama | Getty Images
Walgreens on Thursday offered soft profit guidance and reported fiscal fourth-quarter earnings that fell short of expectations, as demand for Covid vaccines and tests sinks in the U.S.
The retail pharmacy giant – squeezed by the transition out of the Covid pandemic, a leadership shake-up, its wobbly push into health-care and recent labor pressure from pharmacy staff – has now underperformed Wall Street’s adjusted earnings expectations for two straight quarters. The last time Walgreens posted a consecutive earnings miss was nearly a decade ago.
The company said it expects adjusted earnings per share of $3.20 to $3.50 in the coming fiscal year, which is lower than analysts’ estimate of $3.72. Walgreens expects lower Covid-related sales, along with a higher tax rate and lower sale and leaseback contributions, to offset earnings growth.
Walgreens also sees revenue for the year at $141 billion to $145 billion. Wall Street analysts estimated sales of more than $144 billion.
Here’s what Walgreens reported compared with what Wall Street was expecting, based on a survey of analysts by LSEG, formerly known as Refinitiv:
- Earnings per share: 67 cents adjusted vs. 69 cents expected
- Revenue: $35.42 billion vs. $34.78 billion expected
The company reported a net loss of $180 million, or 21 cents per share, for the fiscal fourth quarter. That compares with a net loss of $415 million, or 48 cents per share, during the same period a year ago. Excluding certain items, adjusted earnings per share were 67 cents for the quarter.
Walgreens booked sales of $35.42 billion in the quarter, which is up roughly 9% from the same period a year ago due to growth in its U.S. retail pharmacy and international business segments.
Sales in the company’s U.S. health-care division also grew. Walgreens noted in a release that it is “intently focused on accelerating” that segment’s profitability moving forward.
The quarterly results come two days after Walgreens named health-care industry veteran Tim Wentworth as its new CEO following the abrupt departure of the company’s former top executive, Roz Brewer, last month. Wentworth, who will take over on Oct. 23, is tasked with steering the retail pharmacy giant out of a rough spot.
Walgreens has made significant investments to transform from a major drugstore chain to a large health-care company. But the pharmacy chain is facing a number of challenges in that transition, including a profit squeeze due to softer consumer spending and declining demand for Covid products as patients emerge from the pandemic.
Walgreens is also facing an open revolt among pharmacists and pharmacy technicians, several of whom staged a three-day walkout this week to protest chronic understaffing and other poor working conditions.
Shares of Walgreens have dropped more than 39% for the year, putting the company’s market value at $19.51 billion.
Three segments post sales growth
Walgreens’ U.S. retail pharmacy segment generated $27.66 billion in sales in the fiscal fourth quarter, an increase of 3.7% from the same period last year. Comparable sales at individual locations rose 5.7%.
Pharmacy sales for the quarter increased 6.4% compared with the fiscal fourth quarter of 2022, with comparable sales up more than 9% due to price inflation in brand medications and mix impacts.
Total prescriptions filled in the quarter, including immunizations, decreased by 0.5% to 297 million. Walgreens cited a weaker respiratory virus season this fall, which is blunting demand for medications and vaccines.
Retail sales for the quarter decreased 4.3% compared with the same period a year ago, and comparable retail sales fell 3.3%.
